Spondyloarthritis
Dr. John Cush RheumNow
1 year 11 months ago
Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108).
- 27% flared at 2/3 dose
- 20% at 1/2 dose
- 27% at 1/3 dose
- 25% w/ discontinuation
WHY WOULD YOU DO THIS? I DONT! https://t.co/g8L7E4lcqG https://t.co/oaBILUrlmd
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD. https://bit.ly/47dT6x6
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Dr. John Cush RheumNow
1 year 11 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5
Dr. John Cush RheumNow
1 year 11 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Dr. John Cush RheumNow
2 years ago
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/7juI2Dghjh https://t.co/SxCaJgTmeQ
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Poster Hall